ImmunityBio Inc
ImmunityBio Inc (IBRX) Unusual Options Activity Today
IBRX's highest volume power reading is 50.00%, on the $4.5 PUT expiring Nov 27, 2026. This strike traded 1 contracts against just 2 in open interest. On the call side, the highest reading is the $5.5 CALL expiring Nov 27, 2026 at 585.71%, with 41 contracts traded against 7 open, as of Nov 20, 2026.
Read more
Checking IBRX unusual options activity helps you spot when traders are making outsized bets on ImmunityBio Inc before the broader market catches on. Unusual activity flags contracts trading at multiples of their average daily volume, often signaling informed money positioning ahead of a catalyst. Use our scanner to monitor IBRX unusual options activity today and surface the prints that deserve a second look.
Unusual options flow typically means volume vastly exceeds open interest at a given strike, or total contract volume on a name spikes well above its norm. Watching IBRX unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking IBRX unusual options volume across calls and puts helps you separate hedging from genuinely speculative positioning, especially valuable around earnings, product launches, and macro events.
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co.
| 5.50 | 0.50 | 1.10 | 0.80 | 159% | 41 | 7 | 585.71% |
| 6.00 | — | 2.45 | 2.45 | 784% | 246 | 66 | 372.73% |
| 5.00 | 0.55 | 1.85 | 1.20 | 182% | 11 | 6 | 183.33% |
| 6.50 | 0.05 | 0.35 | 0.20 | 116% | 122 | 81 | 150.62% |
| 3.00 | 2.70 | 3.70 | 3.20 | 466% | 4 | 11 | 36.36% |
| 4.50 | — | 0.10 | 0.10 | 199% | 1 | 2 | 50.00% |
| 6.50 | 0.15 | 0.65 | 0.40 | 6% | 25 | 53 | 47.17% |
| 7.00 | 0.65 | 1.60 | 1.13 | 140% | 3 | 15 | 20.00% |
| 10.00 | 3.30 | 4.80 | 4.05 | 250% | 2 | 10 | 20.00% |
| 8.00 | 1.50 | 2.80 | 2.15 | 215% | 10 | 158 | 6.33% |
As of Nov 20, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →